Canopy Growth Corporation

Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower

Canopy Growth's Smiths Falls, Ontario facility received EU GMP certification for softgel manufacturing and primary packaging of softgels, oral liquids and dried cannabis flower, from Germany's Tübingen Regional Council. Smiths Falls is now the only Canadian cannabis facility with EU GMP certification covering this combined scope, per an EudraGMDP database review as of October 9, 2026. The certification extends the company's end-to-end EU GMP supply chain connecting Canadian production to European distribution, building on renewed certification at Kincardine and expansion of Spectrum Therapeutics flower into the UK. Management is focused on accelerating commercial execution across Germany, Poland and the UK to serve the European medical cannabis market.

•26d ago

Canopy Growth Expands European Medical Cannabis Supply Into the UK

Canopy Growth will supply four Canadian-grown medical cannabis flower strains to GROW Group U.K. Ltd. for distribution in the United Kingdom, marking the company's entry into the UK medical cannabis market. GROW Group, a British manufacturer and distributor of prescribed cannabis-based medicines, will commercialize the products under Canopy Growth's global Spectrum Therapeutics medical brand. CEO Luc Mongeau framed the UK expansion as another step in growing the company's European medical cannabis business, citing established EU GMP supply capability and growing demand across European medical markets. The launch follows the recent renewal of EU GMP certification at Canopy Growth's Kincardine, Ontario cultivation facility. No financial terms, supply volumes, or revenue expectations were disclosed, so the near-term contribution is likely incremental rather than material.

•1mo ago

Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations

Canopy Growth broadened its Australian medical cannabis portfolio with two new product formats — pastilles and all-in-one vapes — plus expanded oil and softgel formulations and new flower SKUs across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. Both the pastille and all-in-one vape formats are firsts for the company in Australia, and the new Spectrum Flow and Spectrum Sunset oils are its first Australian oils to include CBG and CBN. CEO Luc Mongeau called expansion in established markets like Australia central to the company's international medical strategy, citing global supply-chain strength, while President of Medical Andrew Bevan said the launches respond to prescriber and patient demand for more format and formulation choice.

•2mo ago

Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows

Canopy Growth secured renewed EU GMP certification for its Kincardine, Ontario facility, allowing it to continue supplying Canadian-grown cannabis to European medical markets. The certification solidifies Kincardine’s role as the anchor in the company’s end-to-end supply chain, which connects Canadian cultivation to its distribution site in Sankt Leon-Rot, Germany. This operational milestone coincides with reported momentum in Europe, which drove a 10% year-over-year increase in international cannabis net revenue in the first quarter of fiscal 2027.

•2mo ago

Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses

Canopy Growth reported fiscal Q1 2027 net revenue of $81.2 million, up 13% year-over-year, driven by growth in Canada medical, adult-use, international markets and the Storz & Bickel segment. Adjusted gross margin improved to 31% from 25% in the prior year, while the adjusted EBITDA loss narrowed by 59% to $3.2 million, reflecting the benefits of the MTL Cannabis acquisition and cost reduction initiatives. Despite the operating improvements, free cash outflow increased to $25.7 million from $11.6 million in the prior year, primarily due to working capital timing.

•3mo ago

Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis

Canopy Growth reported Q4 FY2026 net revenue of $71.2 million, up 10% year-over-year, driven by 27% growth in Canada medical cannabis and 68% growth in international markets. Full-year revenue reached $284.6 million, a 6% increase, while the net loss from continuing operations narrowed by 49% to $262.9 million. The company ended the fiscal year with $131.3 million in net cash, a significant turnaround from $172.6 million in net debt a year prior. Management expects to achieve positive Adjusted EBITDA in FY2027, citing improved gross margins, cost discipline, and the integration of MTL Cannabis. Free cash outflow improved dramatically to $69.1 million from $176.6 million in the prior year.

•4mo ago

‘There’s a Tweed for That’: Canopy Growth Announces Tweed Brand Summer Campaign

Canopy Growth is refreshing its Tweed brand with a summer campaign featuring new window packaging, improved potency, and sharper pricing across its portfolio. The rollout introduces three new flower strains—Tropical Gelato Slushie, Citrus Candy Cake, and GMO Jet Fuel—alongside existing favorites like Quickies pre-rolls and Liquid Diamond vapes. CEO Luc Mongeau noted the updates are based on consumer and budtender feedback, aiming to build brand equity through disciplined execution.

•6mo ago